On December 15, Glonghui reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group Co., Ltd. received a written response from the USA Food and Drug Administration (referred to as "FDA") on December 15, 2024. The clinical trial application for WP107 (Huperzine A oral solution), independently developed by the company, for the treatment of "generalized myasthenia gravis" has officially been accepted. WP107 (Huperzine A oral solution) is a new oral formulation for the treatment of generalized myasthenia gravis developed by the company's innovative drug R&D team based on preclinical and clinical data.
万邦德(002082.SZ)：子公司WP107药品临床试验申请获得 FDA 受理
Wanbangde Pharmaceutical Holding Group (002082.SZ): The clinical trial application for its subsidiary WP107 Pharmaceutical has been accepted by the FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated